A Phase 3 interventional study of REGN2810/ipi and REGN2810/chemo/ipi in Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-16.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 28th largest by enrollment, is one of 4 that started in 2018, is one of 5 in phase 3, and was the 4th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Georgetown University · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
UNICANCER · Sites in France
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Austria, Estonia, France and 6 more countries
Ages 18+
Maia Biotechnology · Sites in Poland, Romania, Taiwan and 1 more country
Ages 18+
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 61 across the 29 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 29 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals: 2 open now, 11 under way, 2 of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 18th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2018, is one of 3 in phase 3, and was the 6th registered.
Regeneron Pharmaceuticals’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2008.
3 of the studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06908304Phase 3Maia BiotechnologyA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | 2027-07-31 |
| NCT06088771Icahn School of Medicine at Mount SinaiNeoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | 2026-12-01 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Regeneron Pharmaceuticals’s 21 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of platinum-based doublet chemotherapy plus ipilimumab combination therapy (hereinafter referred to as "REGN2810/chemo/ipi") with standard-of-care pembrolizumab monotherapy in the first-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC) whose tumors express programmed death ligand 1 (PD-L1) in ≥50% of tumor cells. The key secondary objectives of the study are to compare the overall survival (OS) of REGN2810/ipi and REGN2810/chemo/ipi with pembrolizumab monotherapy in the first-line treatment of patients with advanced squamous or non-squamous NSCLC whose tumors express PD-L1 in ≥50% of tumor cells and to compare the overall response rate (ORR) of REGN2810/ipi and REGN2810/chemo/ipi with pembrolizumab monotherapy in the first-line treatment of patients with advanced squamous or non-squamous NSCLC whose tumors express PD-L1 in ≥50% of tumor cells.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pembrolizumab
Drug: Pembrolizumab
REGN2810/ipi
Drug: REGN2810/ipi
REGN2810/chemo/ipi
Drug: REGN2810/chemo/ipi
Drug page: Cemiplimab
REGN2810 plus ipilimumab
Also known as: cemiplimab
Drug page: Cemiplimab
REGN2810 plus chemotherapy plus Ipilimumab
Also known as: cemiplimab
Reference drug administered IV infusion
This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.
Progression-Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessments
Per protocol, the final analysis of PFS was to be performed after observing 142 PFS events in the pembrolizumab treatment arm. PFS was not assessed due to insufficient data collected.
Time frame: Up to 32 months
Overall Survival (OS)
Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.
Time frame: Up to 32 months
Objective Response Rate (ORR)
Per protocol, the ORR for each cemiplimab combination-versus-pembrolizumab comparison was to be analyzed using the Cochran-Mantel-Haenszel test stratified by histological status (non-squamous versus squamous).
Time frame: Up to 32 months
Number of Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to 32 months
Number of Participants With Dose-Limiting Toxicities (DLTs)
Time frame: Up to 32 months
Number of Participants With Any Serious TEAEs
Time frame: Up to 32 months
Number of Participants With TEAEs Leading to Death
Time frame: Up to 32 months
Number of Participants With Laboratory Abnormalities
Time frame: Up to 32 months
Overall Survival (OS) at 12 Months
Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.
Time frame: At 12 months
Overall Survival (OS) at 18 Months
Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.
Time frame: At 18 months
Quality of Life (Core 30 Questionnaire)
Quality of Life (QoL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) four-point scale, with 1 as "not at all" and 4 as "very much." Per protocol, the change in EORTC QLQ-C30 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.
Time frame: Up to 32 months
Quality of Life (Lung Cancer 13 Questionnaire)
QoL as measured by the Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) to assess lung cancer-associated symptoms and treatment-related side effects among lung cancer patients. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much." Per protocol, the change in EORTC QLQ-LC13 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.
Time frame: Up to 32 months
This study was conducted at 3 centers that randomized 5 participants in the United States, Lithuania, and Italy.
| Milestone | Pembrolizumab | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|---|
| Started | 0 | 3 | 2 |
| Completed | 0 | 1 | 1 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Progressive disease | 0 | 1 | 0 |
Per protocol, the final analysis of PFS was to be performed after observing 142 PFS events in the pembrolizumab treatment arm. PFS was not assessed due to insufficient data collected.
No measurements were reported for this outcome.
Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.
No measurements were reported for this outcome.
Per protocol, the ORR for each cemiplimab combination-versus-pembrolizumab comparison was to be analyzed using the Cochran-Mantel-Haenszel test stratified by histological status (non-squamous versus squamous).
No measurements were reported for this outcome.
| Events | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| Number of Treatment-Emergent Adverse Events (TEAEs) | 68 | 91 |
| Participants | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) | 0 | 0 |
| Participants | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| Number of Participants With Any Serious TEAEs | 2 | 2 |
| Participants | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| Number of Participants With TEAEs Leading to Death | 1 | 0 |
| Participants | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| Number of Participants With Laboratory Abnormalities | 1 | 1 |
Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.
No measurements were reported for this outcome.
Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.
No measurements were reported for this outcome.
Quality of Life (QoL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) four-point scale, with 1 as "not at all" and 4 as "very much." Per protocol, the change in EORTC QLQ-C30 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.
| Score on a scale | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| Quality of Life (Core 30 Questionnaire) | NA ± NA | NA ± NA |
QoL as measured by the Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) to assess lung cancer-associated symptoms and treatment-related side effects among lung cancer patients. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much." Per protocol, the change in EORTC QLQ-LC13 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.
| Score on a scale | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| Quality of Life (Lung Cancer 13 Questionnaire) | NA ± NA | NA ± NA |
Collected over From first dose of study drug to end of study (up to 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| Event | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| PericarditisCardiac disorders | 0/3 | 1/2 |
| HyponatraemiaMetabolism and nutrition disorders | 0/3 | 1/2 |
| Secondary adrenocortical insufficiencyEndocrine disorders | 1/3 | 0/2 |
| EnterocolitisGastrointestinal disorders | 1/3 | 0/2 |
| GastritisGastrointestinal disorders | 1/3 | 0/2 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/3 | 0/2 |
| Cytokine release syndromeImmune system disorders | 1/3 | 0/2 |
| Back painMusculoskeletal and connective tissue disorders | 1/3 | 0/2 |
| Event | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/3 | 2/2 |
| LeukopeniaBlood and lymphatic system disorders | 0/3 | 2/2 |
| Abdominal pain upperGastrointestinal disorders | 1/3 | 2/2 |
| NauseaGastrointestinal disorders | 1/3 | 2/2 |
| Chest painGeneral disorders | 0/3 | 2/2 |
| FatigueGeneral disorders | 2/3 | 2/2 |
| FallInjury, poisoning and procedural complications | 0/3 | 2/2 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 2/2 |
| HypokalaemiaMetabolism and nutrition disorders | 1/3 | 2/2 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/3 | 2/2 |
Safety analysis set (SAF), defined as all enrolled participants who received any amount of study treatment.
| Age, Continuous(Years) | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W | Total |
|---|---|---|---|
| Mean | 61.7 ± 9.29 | 56.5 ± 4.95 | 59.6 ± 7.57 |
| Sex: Female, Male(Participants) | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W | Total |
|---|---|---|---|
| Female | 3 | 0 | 3 |
| Male | 0 | 2 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W | Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 2 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Jul 2021, 36 months.
Results were first posted in Nov 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab
Carcinoma, Non-Small-Cell Lung →